Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News on Diabetes

New ‘unusual’ side effect of weight-loss drugs becoming more common, research suggests

GLP-1 drugs may interfere with medical imaging, leading to unnecessary tests, researchers have found

The Independent UK

Costco to start selling Ozempic and Wegovy at discounted prices

The Independent UK

Childhood Obesity: How Parents Can Help Their Kids Who Are Overweight

Learn how to help your child who is experiencing being overweight and avoid getting into obesity.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

If I wanted to improve my peri- and menopause symptoms I’d follow this expert’s dietary advice

How fiber could be your secret weapon for managing menopause

Fit & Well

Ban on 'buy one, get one free' deals on unhealthy foods comes into place

The UK Government is implementing a ban on the promotion of unhealthy foods as part of a broader health initiative.

Evening Standard

Weight-loss jabs should be available to millions more on NHS, Streeting suggests

Health should not be determined by wealth, says Wes Streeting at the Labour Party conference

The Independent UK

Why you might actually be healthier if you put on weight

A new study has linked higher mortality rates with people in the middle and lower end of the normal weight range

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Easier access to prescriptions as nurses' powers grow

Qualified nurses will help alleviate the burdens on the health system by providing patients with another avenue for their prescriptions.

AAP

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch

On Wednesday, Eli Lilly Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Benzinga

DNA test reveals which weight loss drug could work best for you

With a growing number of people turning to weight loss drugs, a new study suggests that some weight loss drugs work better than others depending on your DNA.

Evening Standard

Scientists surprised to find human body makes its own Ozempic version

Study finds body’s ‘built-in backup plan’ for diabetes-controlling hormone production

The Independent UK

Trump to link autism to Tylenol use during pregnancy

The mention of a connection would revive a medical controversy over the use of acetaminophen early in a pregnancy.

Axios

Could This New Drug Be The Safer Way To Fight Obesity?

On Friday, Skye Bioscience, Inc. (NASDAQ:SKYE) announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting.

Benzinga

Five o’clock dinner crowd: why are young Americans eating so early?

Gen Z and millennials’ dinner reservations are reportedly inching earlier as they take advantage of happy hour deals

The Guardian - US

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Daily arthritis pill could slow progression of diabetes, trial finds

The drug is already used to treat several autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, and alopecia

Benzinga

Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal

Novo Nordisk A/S (NYSE:NVO) looks ready to shake off its slump. With weight-loss pills showing blockbuster results, Ozempic proving heart-healthy benefits, and analysts flipping bullish, the stock is starting to resemble UnitedHealth Group Inc.'s (NYSE:UNH) rebound playbook.

Benzinga

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device.

The Independent UK

‘Pioneering’ new weight-loss jab could help keep weight off even after you stop taking it

The downfall of drugs such as Mounjaro, Ozempic and Wegovy is many patients regain weight shortly after stopping

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss?

Eli Lilly and Co (NYSE:LLY) on Tuesday shared detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of oral orforglipron in adults with obesity, or overweight with a weight-related medical problem, and without diabetes.

The Independent UK

Vital breakthrough as once-a-day pill can help people lose ‘significant’ weight

A fifth of people taking the weight-loss tablet Orforglipron lost 20 per cent of their body weight

The Independent UK

Study recommends ‘planetary diet’ to cut diabetes risk and emissions

Researchers say dietary changes are crucial part of effort to tackle global heating

The Independent UK

Weight-loss drugs help stop intrusive thoughts about food, study finds

Wegovy also was found to improve mental health, self-confidence and the development of healthier habits

Benzinga

Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment

Novo Nordisk A/S (NYSE:NVO) reportedly said on Tuesday that it intends to seek US regulatory approval for a high-dose version of its weight-loss injection Wegovy (semaglutide), another effort to counter Eli Lilly and Co. (NYSE:LLY).

Evening Standard

Weight loss jabs could be effective on children as young as six, study suggests

The report did warn that stomach problems are more common among youngsters taking the drugs.

The Independent UK

Obese children as young as six could benefit from weight-loss jabs

About a third of children leaving primary school are overweight or living with obesity in England

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.